BERKELEY, CA--(Marketwire - Mar 21, 2013) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the appointment of David Novack to the position of Senior Vice President, Operations and Quality, effective March 25, 2013. Mr. Novack brings nearly 25 years of industry experience in manufacturing and supply chain operations, implementing multi-national commercial manufacturing and supply chain strategies for both global industry leaders and emerging companies in vaccines, diagnostics, and biopharmaceuticals. Mr. Novack will be joining Dynavax from Novartis Vaccines & Diagnostics where he served most recently as the Global Head of Technical Operations and Supply Chain for Diagnostics, and previously as the Global Head of Vaccine Manufacturing Strategy. During his tenure at Novartis, Mr. Novack successfully developed and executed manufacturing capacity plans to meet commercial requirements, designed and executed remediation programs to be compliant with current quality standards, and was responsible for cost-effective supply chain solutions across multiple product lines.

"David's background and experience will be a valuable addition to our senior management team," said President and Chief Medical Officer, Tyler Martin, M.D. "We look forward to his contributions in the planning and implementation of a successful commercial manufacturing strategy for the advancement of HEPLISAV™ and long-term growth of the Company."

Prior to Novartis, Mr. Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr. Novack worked at MedImmune, formerly Aviron, serving in several capacities including business development, manufacturing, contract operations and most recently as Senior Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr. Novack was with American Cyanamid Company in various roles. Mr. Novack received a B.S. in Biology from State University of New York and an M.B.A. from Columbia University.

Dynavax also reported that Stephen Tuck, Vice President, Global Technical Operations, will be departing the Company as of March 29, 2013. Said Chief Executive Officer, Dino Dina, M.D., "I want to personally express my appreciation for Stephen's many years of service and commitment to Dynavax dating back nearly to the inception of the Company."

President and Chief Medical Officer, Tyler Martin, M.D., commented, "Stephen's leadership and expertise in Technical Operations was critical to the HEPLISAV™ program over the past two years, in particular for the submission of our U.S. and European regulatory applications for HEPLISAV. We greatly appreciate his contributions to Dynavax."

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit

Contact Information:

Michael Ostrach
Vice President and Chief Business Officer